Insulin Pump Program
The Australian Government’s Insulin Pump Program provides subsidies to low income families who have children with type 1 diabetes. The Program aims to improve access and and affordability of insulin pumps for limited income families who have children (up to 18 years of age) with type 1 diabetes, and do not have access to other means of reimbursement, such as private health insurance. Since its inception in 2008, the Program has provided over 950 subsidised pumps to children with type 1 diabetes.
Program activities for the 2018-19 financial year have commenced and JDRF Australia will be contacting families who are on the expression of interest list to advise of the next steps in progressing their applications.
To improve access to the Program, the Government has introduced a number of changes to the Program arrangements, effective from September 2018:
- The Government has established a panel of suppliers to supply pumps to the recipients under this Program. The following pumps will be available under the Insulin Pump Program: Accu-Chek Spirit Combo (Roche), MiniMed 640G (Medtronic) and Paradigm Veo (Medtronic). These pumps will be supplied with approximately three months’ initial supply of pump consumables.
- The expected number of pumps subsidised under the Program, in each financial year, is expected to increase from up to 68 pumps per year to approximately 220 pumps per year.
Subject to meeting with the Program criteria, families with a combined annual income of up to $109,610 will be able to apply for a pump subsidy under the Program.
Eligible families will be required to discuss the suitability of insulin pump therapy with their child’s Healthcare Team and if deemed clinically suitable, would discuss which of the above pumps is best for their child.
There are a limited number of subsidised pumps available under the Program in each financial year and therefore JDRF Australia is unable to guarantee that all families who have expressed an interest will be receiving a pump under the Program in any given financial year.
Priority access will be given to those who applied for an insulin pump subsidy between 1 July 2017 and 30 June 2018 and were placed on a waiting list after previous funding was exhausted. All applications received after 30 June 2018 will remain on hold until the priority list is exhausted or further funding is allocated.
Report: Aussie adults with type 1 diabetes unable to access life-changing technology due to high cost
Young adults and low-income families with type 1 diabetes (T1D) are facing immense barriers to using and retaining vital technology to manage their disease, with inequitable access and high costs putting them at risk of financial burden and life-threatening complications. The financial burden of managing T1D is exacerbating mental health issues with half of those […]
T1D Research Roundup: March 2021
Our research roundups bring you the most exciting T1D research stories from around the world – the new advances in treatment, devices and knowledge that are making the biggest impact in the fight to cure, treat and prevent T1D. Here’s what you need to know in T1D research this month: Monash University researchers crack the […]
COVID-19 Vaccines and T1D: Answering Your Questions
Australia has begun the rollout of two COVID-19 vaccines — one from Pfizer, and one from AstraZeneca. Both these vaccines are safe and effective at protecting people against COVID-19, and all Australians are encouraged to get vaccinated. With vaccines beginning to be offered to people with T1D, we’ve gathered all the information you need to […]
Top 10 T1D Research Breakthroughs of 2020
While COVID-19 has dominated the news in 2020, it’s also been a huge year for type 1 diabetes research. This year, we’ve made more progress than ever on our mission to cure, treat and prevent T1D – including new insights into what causes the disease, some incredible results from prevention therapies, and the launch of […]